Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CoLucid Pharmaceuticals Inc.

Division of Eli Lilly & Co.
www.colucid.com

Latest From CoLucid Pharmaceuticals Inc.

Lilly's Lasmiditan NDA Review Could Hinge On US FDA's Migraine Guidance

Potential first-in-class on-demand oral migraine treatment would complement new prevention products from Lilly, Amgen and Teva. 
Neurology Drug Review

Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?

Galcanezumab was able to reduce episodic cluster headaches compared to placebo, but missed statistical significance for chronic cluster headaches. Amgen’s Aimovig still is first in line to reach the market in the anti-CGRP class.

Neurology Clinical Trials

Lilly Reacquires Aurora Kinase Inhibitor Via AurKa Buy For $110m

Many Aurora kinase inhibitors have entered development, but while none have had a successful end, Lilly believes the specificity of AurKa's AK-01 will make it a safer drug. The asset fits well into Lilly's oncology strategy, which includes both targeted therapies and immuno-oncology drugs.

Deals Cancer

Allergan's Ubrogepant Succeeds In Second Acute Migraine Phase III Study

The company intends to seek US FDA approval in the first half of 2019 for its CGRP inhibitor and believes that liver toxicity previously associated with oral drugs in this class are not a problem for its candidate ubrogepant.

Clinical Trials Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Eli Lilly & Co.
  • Senior Management
  • Thomas P Mathers, CEO
    Linda Hogan, Head,, Bus. Dev. & Strategy
    Bernice Kuca, Head, Clin. & Reg. Operations
  • Contact Info
  • CoLucid Pharmaceuticals Inc.
    Phone: (857) 285-6495
    222 Third St.
    Ste. 1320
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register